Phase II Trial of SBRT and Hormone Therapy for Oligometastases in Prostate Cancer

被引：2

作者：

Conde-Moreno, A. J. ^{[1
]}

Lopez, F. ^{[2
]}

Hervas, A. ^{[2
]}

Piquer Camanes, T. ^{[3
]}

Mendez, A. ^{[4
]}

Puertas, M. D. M. ^{[5
]}

Valero, J. J. ^{[6
]}

Gomez Iturriaga, A. ^{[7
]}

Rico, M. ^{[8
]}

Vazquez de la Torre, M. L. ^{[9
]}

Samper Ots, P. M. ^{[10
]}

Perez Romasanta, L. A. ^{[11
]}

Pastor Peidro, J. ^{[12
]}

Ibanez, C. ^{[13
]}

Ferrer, F. ^{[14
]}

Porras-Martinez, M. ^{[15
]}

Zapatero, A. ^{[16
]}

Garcia Blanco, A. S. ^{[17
]}

Rodriguez, A. ^{[18
]}

Ferrer, C. ^{[19
]}

机构：

[1] Hosp Univ & Politecn La Fe, Valencia, Spain

[2] Hosp Univ Ramon y Cajal, Madrid, Spain

[3] Consorcio Hosp Prov Castellon, Castellon de La Plana, Spain

[4] Miguel Servet Univ Hosp, Zaragoza, Spain

[5] Hosp Miguel Servet, Zaragoza, Spain

[6] Univ Hosp HM Sanchinarro Puerta del Sur, Madrid, Spain

[7] Cruces Univ Hosp, Baracaldo, Spain

[8] Complejo Hosp Navarra, Pamplona, Spain

[9] Hosp Meixoeiro, Vigo, Spain

[10] Hosp Univ Rey Juan Carlos, Madrid, Spain

[11] Hosp Clin Salamanca, Salamanca, Spain

[12] Hosp Gen Valencia, Valencia, Spain

[13] Hosp Cent Def Gomez Ulla, Madrid, Spain

[14] Catalan Inst Oncol, Dept Radiat Oncol, Lhospitalet Barcelona, Spain

[15] Hosp Univ Virgen de la Arrixaca, Murcia, Spain

[16] Hosp Univ La Princesa, Madrid, Spain

[17] Hosp Univ Marques de Valdecilla, Santander, Spain

[18] Hosp Ruber, Madrid, Spain

[19] Hosp Prov Castellon, Castellon de La Plana, Spain

来源：

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2019年 / 105卷 / 01期

关键词：

D O I：

10.1016/j.ijrobp.2019.06.155

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1075

引用

页码：S149 / S150

页数：2

共 50 条

[41] Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer
Kumar Rajagopalan
David Peereboom
G. Thomas Budd
Thomas Olencki
Siva Murthy
Paul Elson
Denise McLain
Ronald Bukowski
Investigational New Drugs, 1998, 16 : 255 - 258
[42] A phase II trial of CI-958 in patients with hormone-refractory prostate cancer
Paul V. Woolley
Fuad S. Freiha
David C. Smith
Lynn Carlson
Janie Hofacker
Nancy Quinn
William Grove
Donald L. Trump
Cancer Chemotherapy and Pharmacology, 1999, 44 : 511 - 517
[43] Atrasentan delayed PSA progression in a phase II trial of men with hormone refractory prostate cancer
Schulman, C
Nelson, JB
Weinberg, MA
Humerickhouse, RA
Schmitt, JL
Nabulsi, AA
JOURNAL OF UROLOGY, 2002, 167 (04): : 176 - 176
[44] A phase II trial of CI-958 in patients with hormone-refractory prostate cancer
Woolley, PV
Freiha, FS
Smith, DC
Carlson, L
Hofacker, J
Quinn, N
Grove, W
Trump, DL
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (06) : 511 - 517
[45] Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer
Rajagopalan, K
Peereboom, D
Budd, GT
Olencki, T
Murthy, S
Elson, P
McLain, D
Bukowski, R
INVESTIGATIONAL NEW DRUGS, 1998, 16 (03) : 255 - 258
[46] Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer
Borrega, P
Velasco, A
Bolaños, M
Pérez, MD
Mel, JR
Reina, JJ
Rodríguez-Jaraiz, MA
Chaves, M
González-Barón, M
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2004, 22 (01) : 32 - 35
[47] PHASE-II TRIAL OF ECHINOMYCIN IN ADVANCED HORMONE-RESISTANT PROSTATE-CANCER
SHEVRIN, DH
LAD, TE
GUINAN, P
KILTON, LJ
GREENBURG, A
JOHNSON, P
BLOUGH, RR
HOYER, H
INVESTIGATIONAL NEW DRUGS, 1994, 12 (01) : 65 - 66
[48] Phase II trial of weekly docetaxel, zoledronic acid and selenium for hormone refractory prostate cancer
Kattan, J. G.
Ghosn, M.
Chahine, G.
Saroufim, A.
Nasr, F.
Farhat, F. S.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[49] Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer
Simons, JW
Carducci, MA
Mikhak, B
Lim, M
Biedrzycki, B
Borellini, F
Clift, SM
Hege, KM
Ando, DG
Piantadosi, S
Mulligan, R
Nelson, WG
CLINICAL CANCER RESEARCH, 2006, 12 (11) : 3394 - 3401
[50] ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial
Marvaso, Giulia
Corrao, Giulia
Zaffaroni, Mattia
Vincini, Maria Giulia
Lorubbio, Chiara
Gandini, Sara
Fodor, Cristiana
Netti, Sofia
Zerini, Dario
Luzzago, Stefano
Mistretta, Francesco Alessandro
Venetis, Konstantinos
Cursano, Giulia
Burla, Tiziana
Mazzocco, Ketti
Cattani, Federica
Petralia, Giuseppe
Fusco, Nicola
Pravettoni, Gabriella
Musi, Gennaro
De Cobelli, Ottavio
Tang, Chad
Ost, Piet
Palma, David A.
Orecchia, Roberto
Jereczek-Fossa, Barbara Alicja
LANCET ONCOLOGY, 2025, 26 (03): : 300 - 311

← 1 2 3 4 5 →